Navigation Links
News briefs from the journal Chest, August 2007
Date:8/13/2007

Patients With OSA Could Benefit From Diuretics

Patients suffering from obstructive sleep apnea (OSA) and diastolic heart failure may find relief in the form of diuretics, according to a new study. Italian researchers treated 15 patients hospitalized with severe OSA, hypertension, and diastolic heart failure, with intravenous diuretics. Patients were treated twice daily for 3 days, and polysomnography was used to assess apnea severity before and after diuretic treatment. After 3 days, researchers found significant improvement in sleep-disordered breathing and an increase in upper airway caliber. They also reported a substantial decrease in patients body weight and blood pressure. This study appears in the August issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians.

Which Line of Antibiotics Is Best for Chronic Bronchitis?

First-line antibiotics traditionally consist of common agents, such as amoxicillin and ampicillin. But according to researchers from the United States and Greece, second-line antibiotic use in patients with acute exacerbation of chronic bronchitis (AECB) is becoming greater, citing an increase in first-line drug resistance among the AECB population. In such instances, macrolides or quinolones are often administered as advanced or second-line antibiotics. To compare the effectiveness of first- and second-line antibiotics, researchers evaluated patients with AECB from 12 randomized control trials. They found that second-line antibiotics were more effective, and that there was no difference in mortality or safety, when compared with first-line antibiotics. This study appears in the August issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians.

Gender Difference in CT-Measured Emphysema Identified

A new study reveals that in men with chronic obstructive pulmonary disease (COPD), at all stages of severity, men have more CT-measurable
'/>"/>

Contact: Jennifer Stawarz
jstawarz@chestnet.org
847-498-8306
American College of Chest Physicians
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Journal Recommends How To Improve The Performance Of Health Workers
2. Medical Journals should create awareness on Child survival
3. A journal’s report on stress, among pregnant wome
4. Canadian Medical Association Journals Editorial Mess Gets Murkier
5. Journalists Blamed For Bird Flu Spread Across Israel
6. Future of Canadian Medical Association Journal Threatened
7. Journalist Petitions Court Pleading Mercy Killing
8. The British Medical Journal Launches A Health Website
9. Springer slated to spring a journal on Brain Imaging and Behavior
10. Journal of Craniofacial Surgery Publishes Research by Iraqi Surgeons
11. Delhi journalism student commits suicide
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Roper Industries Completes the Acquisition of Verathon, Inc. 2Roper Industries Completes the Acquisition of Verathon, Inc. 3Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 2Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 3Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 4Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 2Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 3Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 4Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 6Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 7Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 14 2009 56735 1Tianyin Pharmaceutical Co Inc Has Four Products Included in Chinas Essential Drug List 56734 1Tianyin Pharmaceutical Co Inc Has Four Products Included in Chinas Essential Drug List 56734 2Tianyin Pharmaceutical Co Inc Has Four Products Included in Chinas Essential Drug List 56734 3MDS Reports Third Quarter 2009 Financial Results 56733 1MDS Reports Third Quarter 2009 Financial Results 56733 2MDS Reports Third Quarter 2009 Financial Results 56733 3MDS Reports Third Quarter 2009 Financial Results 56733 4MDS Reports Third Quarter 2009 Financial Results 56733 5MDS Reports Third Quarter 2009 Financial Results 56733 6MDS Reports Third Quarter 2009 Financial Results 56733 7MDS Reports Third Quarter 2009 Financial Results 56733 8MDS Reports Third Quarter 2009 Financial Results 56733 9MDS Reports Third Quarter 2009 Financial Results 56733 10MDS Reports Third Quarter 2009 Financial Results 56733 11MDS Reports Third Quarter 2009 Financial Results 56733 12MDS Reports Third Quarter 2009 Financial Results 56733 13MDS Reports Third Quarter 2009 Financial Results 56733 14MDS Reports Third Quarter 2009 Financial Results 56733 15MDS Reports Third Quarter 2009 Financial Results 56733 16MDS Reports Third Quarter 2009 Financial Results 56733 17MDS Reports Third Quarter 2009 Financial Results 56733 18MDS Reports Third Quarter 2009 Financial Results 56733 19MDS Reports Third Quarter 2009 Financial Results 56733 20MDS Reports Third Quarter 2009 Financial Results 56733 21MDS Reports Third Quarter 2009 Financial Results 56733 22MDS Reports Third Quarter 2009 Financial Results 56733 23
Other Medicine Technology:NIEHS Researchers Identify Enzyme Critical in DNA Replication 2NIEHS Researchers Identify Enzyme Critical in DNA Replication 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8